ClinicaliQ Trial Snapshot
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis — Recruiting • Phase II • NCT07013201.
- Delgocitinib cream twice daily reduced symptoms of palmoplantar pustulosis more effectively than placebo cream over 16 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits. Conditions: Palmoplantar Pustulosis Interventions: Delgocitinib cream, Vehicle cream Lead Sponsor: LEO Pharma Planned Enrollment: 135 participants